Vifor Pharma Group: Kapruvia receives positive CHMP opinion

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Committee for Medicinal Products for Human Use (CHMP) recommends approval of Kapruvia(difelikefalin) as first therapy in Europe for the treatment of

Related Keywords

Norway , Iceland , United States , Liechtenstein , Switzerland , Swiss , Christopher Posner , Vifor Pharma , Iris Francesconi , Klaus Henning Jensen , Annie Spinetta , Nathalie Ponnier , Instagram , Linkedin , Twitter , International Journal Of Nephrology , Nasdaq , Cara Therapeutics Inc , Vifor Pharma Group , European Union , National Registry Study , Committee For Medicinal Products Human Use , Swiss Stock Exchange , European Commission , Global Head Corporate Communications , Swiss Exchange , Exchange Commission , European Medicines Agency , Fresenius Medical Care , Medicinal Products , Human Use , Fresenius Medical Care Renal Pharma , Cara Therapeutics , Chief Medical Officer , Chief Executive Officer , Cara Therapeutic , Pharma Group , Sanifit Therapeutics , Vifor Fresenius Medical Care Renal Pharma , Chronic Kidney Disease Associated Pruritus , Registry Study , Private Securities Litigation Reform Act , Quarterly Report , Dialysis Outcomes , Practice Patterns , Nephrol Dial , Patient Reported Outcomes , Uremic Pruritus , Head Corporate Communications , Relations Treasury Senior Manager , Vifor , Dharma , Group , Apruvia , Eceives , Positive , Thmp , Opinion , Treatment , Moderate , Evere , Pruritus , Hemodialysis , Patients ,